Literature DB >> 22290318

[Surgery for neuroendocrine tumors of the gastroenteropancreatic system (GEP-NET)].

P E Goretzki1, A Starke, A Akca, B J Lammers.   

Abstract

Surgical treatment is still the only curative treatment proven for patients with neuroendocrine tumors (NET) of the gastroenteropancreatic system. In addition to the therapy of incidental findings, the treatment of NET with variable aggressiveness and often good long-term prognosis requires a thorough preoperative assessment and a surgical procedure that is based on each individual case. Treatment can be surgery alone (if the disease is locally confined) or can be combined with other therapies. Early NET of the stomach and rectum can be cured endoscopically without further diagnostics, while early findings of the appendix can be treated by an appendectomy. Functionally active pancreatic NET and NET of the small intestine are often preoperatively diagnosed based on symptoms. Thus, it is possible to refer the patient to a NET center, if necessary. Stratification of the necessary treatment combination can be made early. An alternative to radical surgical treatment is the operative reduction of the tumor size and hormone production in metastasized NET, which can lead to improved life expectancy and quality of life. Combination with other treatment forms is absolutely necessary in these patients. It has been proven useful to divide the large group of NET based on the different tumor locations, hormone activity, and the degree of differentiation of the tumor. Early forms, locoregionally limited tumor stages, and tumor stages with distant metastases are considered separately.

Entities:  

Mesh:

Year:  2012        PMID: 22290318     DOI: 10.1007/s00108-011-2917-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  28 in total

Review 1.  [Diagnostics and treatment in functional pancreatic neuroendocrine tumours].

Authors:  K Müssig; K Dudziak; M Horger; M Anlauf; P E Goretzki
Journal:  Dtsch Med Wochenschr       Date:  2011-06-07       Impact factor: 0.628

Review 2.  [Pancreatic hyperinsulinism--changes of the clinical picture and importance of differences in sporadic disease course (experience with 144 patients operated in the period 1986-2009)].

Authors:  P Goretzki; A Starke; B Lammers; K Schwarz; H-D Röher
Journal:  Zentralbl Chir       Date:  2010-06-17       Impact factor: 0.942

3.  Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome.

Authors:  Martin Anlauf; Regina Schlenger; Aurel Perren; Juliane Bauersfeld; Christian A Koch; Henning Dralle; Andreas Raffel; Wolfram T Knoefel; Eberhard Weihe; Philippe Ruszniewski; Anne Couvelard; Paul Komminoth; Philipp U Heitz; Günter Klöppel
Journal:  Am J Surg Pathol       Date:  2006-05       Impact factor: 6.394

Review 4.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

5.  Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms.

Authors:  Paul G Gauger; Gerard M Doherty; James T Broome; Barbra S Miller; Norman W Thompson
Journal:  Surgery       Date:  2009-10       Impact factor: 3.982

6.  Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas.

Authors:  Jonathan Strosberg; Nancy Gardner; Larry Kvols
Journal:  Pancreas       Date:  2009-04       Impact factor: 3.327

7.  Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors?

Authors:  Laureano Fernández-Cruz; Laia Blanco; Rebeca Cosa; Héctor Rendón
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

8.  Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer.

Authors:  Michael G House; John L Cameron; Keith D Lillemoe; Richard D Schulick; Michael A Choti; Donna E Hansel; Ralph H Hruban; Anirban Maitra; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-01       Impact factor: 3.267

Review 9.  Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors.

Authors:  Matthew H Kulke; Johanna Bendell; Larry Kvols; Joel Picus; Rodney Pommier; James Yao
Journal:  J Hematol Oncol       Date:  2011-06-14       Impact factor: 17.388

10.  Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases.

Authors:  Bruna Estrozi; Carlos E Bacchi
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

View more
  3 in total

Review 1.  Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.

Authors:  Ting-Ting Li; Feng Qiu; Zhi Rong Qian; Jun Wan; Xiao-Kun Qi; Ben-Yan Wu
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 2.  [Surgical approach of gastroduodenal neuroendocrine neoplasms].

Authors:  V Fendrich; D K Bartsch
Journal:  Chirurg       Date:  2016-04       Impact factor: 0.955

Review 3.  [Rectal neuroendocrine tumors: surgical therapy].

Authors:  O Radulova-Mauersberger; S Stelzner; H Witzigmannn
Journal:  Chirurg       Date:  2016-04       Impact factor: 0.955

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.